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Sorafenib, a multi-tyrosine kinase inhibitor, kills more effectively the non-metastatic prostate cancer cell line 22Rv1 than the
highly metastatic prostate cancer cell line PC3. In 22Rv1 cells, constitutively active STAT3 and ERK are targeted by sorafenib,
contrasting with PC3 cells, in which these kinases are not active. Notably, overexpression of a constitutively active MEK
construct in22Rv1cellsstimulatesthe sustainedphosphorylationof Bad andprotectsfromsorafenib-induced celldeath.InPC3
cells, Src and AKT are constitutively activated and targeted by sorafenib, leading to an increase in Bim protein levels.
Overexpression of constitutively active AKT or knockdownof Bim protects PC3 cells from sorafenib-induced killing.In both PC3
and 22Rv1 cells, Mcl-1 depletion is required for the induction of cell death by sorafenib as transient overexpression of Mcl-1 is
protective. Interestingly, co-culturing of primary cancer-associated ﬁbroblasts (CAFs) with 22Rv1 or PC3 cells protected the
cancer cells from sorafenib-induced cell death, and this protection was largely overcome by co-administration of the Bcl-2
antagonist, ABT737. In summary, the differential tyrosine kinase proﬁle of prostate cancer cells deﬁnes the cytotoxic efﬁcacy of
sorafenib and this proﬁle is modulated by CAFs to promote resistance. The combination of sorafenib with Bcl-2 antagonists,
such as ABT737, may constitute a promising therapeutic strategy against prostate cancer.
Cell Death and Disease (2012) 3, e262; doi:10.1038/cddis.2012.1; published online 26 January 2012
Subject Category: Cancer
Prostate cancer is the most frequent malignancy in men
worldwide. Localized prostate cancer is efﬁciently treated by
androgen deprivation therapy, radiotherapy or surgery. Since
2004, when the data from TAX 327 and SWOG 9916 trials
showed survival beneﬁts following docetaxel, this compound
has been standard treatment for patients with metastatic
castration-resistant prostate cancer (CRPC).
1 Unfortunately,
docetaxel treatment has improved survival only modestly with
an average median survival increase compared with mitox-
antrone of B3 months. Multiple tyrosine kinase inhibitors
(TKI) with anti-angiogenic targeting proﬁles such as sorafenib
and sunitinib have been evaluated in metastatic CRPC, but
data are yet limited.
Since 1996, when the ﬁrst attempt was made to proﬁle the
expression of tyrosine kinases in prostate cancer cells,
signiﬁcant progress has been made in mapping the signaling
pathways important for the development of prostate cancer
and in particular CRPC.
2 The activation of both receptor
tyrosine kinases (RTK), such as platelet-derived growth factor
receptor (PDGFR), vascular endothelial growth factor (VEGFR)
and epidermal growth factor receptor (EGFR), and that of non-
receptor tyrosine kinases (NRTK), such as Src and LCK, has
been well described.
3,4 Owing to the critical role of RTK and
NRTK in prostate cancer, they constitute prospective therapeutic
targets for an improved clinical management of CRPC.
The signaling cascades downstream of RTKs and NRTKs
include mainly the Ras/Raf/MEK/ERK, JAK/STAT and the
PI3K/AKT pathways. In particular, the Ras/Raf/MEK/ERK
signaling cascade has a pivotal role in the molecular circuitry
ofCRPC,andthemajorityoftheRTKsupregulatedinprostate
cancer have been shown to activate Ras.
5 Several studies
have shown that the Ras/Raf/MEK/ERK activity positively
correlates with disease progression.
6 As there are very few
reports on activating mutations in the Ras/Raf/MEK/ERK
pathways, it is likely that the autocrine or paracrine activation
of their upstream activators, RTK and NRTK, accounts for the
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www.nature.com/cddisinduction of this pathway. Furthermore, ERK not only
promotes growth but also protects from cell death by
the induction and stabilization of anti-apoptotic proteins
(e.g., Bcl-2, Bcl-xL and Mcl-1) or the inhibition of pro-apoptotic
mediators (e.g., the phosphorylation of Bad).
7
TheothermaindownstreamtargetofRTKsandNRTKs,the
PI3K/AKT pathway has also been increasingly implicated in
the development and progression of prostate cancer. Several
mechanisms have been proposed for the aberrant activation
of the PI3K/AKT pathway, namely activating mutations in the
catalyticsubunitofPI3KandAKT,lossofexpressionofPTEN
and autocrine/paracrine signaling from the RTKs and
NRTKs.
8,9 In fact, PTEN homozygous deletions have been
detected in 20–30% of metastatic prostate cancer and more
than 50% of prostate carcinomas exhibited increased AKT1
kinase activity.
10,11 Thus, AKT has been shown to have a key
role in protecting cells from various types of apoptotic stimuli
byphosphorylatingandinhibiting downstream targetssuchas
the Forkhead family transcription factors, which are known
to regulate, among other proteins, the expression of the
BH3-only protein Bim.
12
The discovery that certain RTKs and NRTKs may be
activated in prostate cancer has opened the way for the
therapeutic usage of TKIs. One clinically established (e.g.,
hepatocellular carcinoma, renal cell carcinoma) TKI is
sorafenib that mainly targets Raf1, PDGFRb, VEGFR, FLT3
and c-Kit.
13 Sorafenib appears to be a good candidate for
the treatment of prostate cancer, because several of the
pathways targeted by this TKI are activated, especially in
CRPC. Thus, sorafenib induces cell death and autophagy in
prostate cancer cell lines, and sorafenib reduces the growth
of human prostate cancers that have been xenografted on
immunodeﬁcient mice (Ullen et al.
14 and personal commu-
nication to Anders Ulle ´n). During the last years, three
independent and rather small phase II trials have evaluated
the effect of sorafenib in CRPC.
15–17
The crosstalk between the tumor microenvironment and
prostate cancer cells is considered to be critical for the
progression of cancer.
18 This is primarily due to the secretion
of cytokines, which in a paracrine fashion (i) activate RTKs
and NRTKs that promote the survival and proliferation of
prostate cancer cells in the development of CRPC and (ii)
activateﬁbroblasts,recruitinﬂammatorycellsandremodelthe
extracellular matrix.
19 Moreover, the tumor stroma can
‘protect’ cancer cells from the cytotoxic insults exerted by
anticancer agent, thus conferring therapeutic resistance. On
theoretical grounds, inhibitors that target tyrosine kinase
signalinginbothcancercellsandthetumormicroenvironment
might be particularly efﬁcient.
In the present study we aimed at delineating the molecular
mechanisms of sorafenib-induced cell death in two prostate
cancer cell lines with distinct metastatic potential. The Raf/
MEK/ERK signaling cascades that leads to phosphorylation/
inactivationofBadandupregulationoftheanti-apoptoticBcl-2
family members is critical for the survival of 22Rv1 cells and
sorafenib, by targeting this signaling cascade is highly
efﬁcacious in killing these cells. In contrast, PC3 cells rely
on the Src/AKT pathway, which in turn leads to inhibition of
Bim expression and targeting of this pathway by sorafenib
sensitizes PC3 cells to apoptosis induction. Inhibition of
cytoprotective autophagy ameliorates sorafenib-induced cell
death. In addition, combination therapy with the Bcl-2
antagonist, ABT737, is particularly effective against the highly
metastatic PC3 cell line and also revert the protection
mediated by cancer-associated ﬁbroblasts (CAFs).
Results
Sorafenib induces caspase-dependent cell death in
Prostate cancer cells. We previously described that
sorafenib- (Sor) induced cell death in 22Rv1 and PC3
prostate cancer cells.
14 Treatment of 22Rv1 and PC3 with
sorafenib led to a time dependent increase in cell death, with
22Rv1 being more sensitive than PC3 cells (Figure 1a).
Sorafenib induced minor changes in the cell cycle distribution
with 22Rv1 exhibiting an S phase arrest and PC3 a G0/G1
arrest (Supplementary Figure 1). Treatment of 22Rv1 with
sorafenib induced a modest decrease in mitochondrial
membrane potential (DCm), as determined with the DCm-
sensitive dye TMRE, and a concomitant increase of cells that
exposed Annexin V. In contrast, PC3 cells responding to
sorafenib demonstrated an almost complete dissipation of
their mitochondrial membrane potential, which was followed by
an increase in the Annexin V
þ population (Figure 1a and b).
However, despite the substantial decrease in DCm,o n l ya
small fraction of cells released cytochrome c from their
mitochondria (Figure 1c).
With the aim to investigate the mechanism of cell death
induced by sorafenib in 22Rv1 and PC3 cells, a number of
classical apoptotic markers were examined (Figure 1d).
22Rv1 cells responding to sorafenib demonstrated cleaved
Bax, activation of caspases, cleavage of PARP and proces-
sing of AIF, characteristic of its translocation to the cytoplasm
(Figure 1d). In PC3, there was only a small increase in active
caspase-7 and PARP cleavage after 48h of treatment. Pre-
treatment of 22Rv1 and PC3 with the broad-spectrum
caspase inhibitor Z-VAD-fmk, followed by sorafenib, partially
inhibited cell death in both cell lines, suggesting that caspase-
dependent processes contribute to cell killing by sorafenib
(Figure 1d). A chemical inhibitor of the pro-necrotic RIP1
kinase, necrostatin1, did not confer signiﬁcant cytoprotection
against sorafenib (Figure 1e). In summary, the data indicate
that 22Rv1 manifest classical signs of apoptosis within 24h of
sorafenib treatment, whereas PC3 cells demonstrate a
reduced and delayed kinetics of apoptosis.
Inhibition of ERK phosphorylation is necessary, but not
sufﬁcient for sorafenib-induced apoptosis in 22Rv1
cells. We determined whether and to which extent
sorafenib might mediate its pro-apoptotic action by
inhibiting the Raf/MEK/ERK pathway. ERK exhibited a
constitutive activating phosphorylation in 22Rv1, and this
phosphorylation was inhibited by sorafenib in a time
dependent manner (Figure 2a and b), whereas ERK was
not activated in PC3 cells. Chemical inhibition of MEK1 with
U0126 by itself induced cell death in 22Rv1 cells, and the
combination of U0126 plus sorafenib did not kill more 22Rv1
cells than sorafenib alone (Figure 2c). U0126 did not have
any effect in PC3 (Figure 2c).
Pro-apoptotic effects of Sorafenib on prostate cancer cells
P Kharaziha et al
2
Cell Death and DiseaseApart from the transcription factors that are regulated by
active ERK 1/2 (e.g., c-fos, ets), a number of apoptosis-related
proteins, such as Bad, are also directly affected.
7 Bad
phosphorylation was partially inhibited by sorafenib, correlat-
ing withtheinhibition ofERKphosphorylation (Figure2d).The
importance of ERK1/2 phosphorylation in sorafenib-induced
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Figure 1 Sorafenib induces caspase-dependent and independent cell death in Prostate cancer cells. (a) Quantitative analysis of Annexin V/PI-positive, 22Rv1 and PC3
cells treated with 20mM sorafenib (Sor) for the indicated time points (means±S.D., nZ3); (b) Quantitative analysis of the loss of mitochondrial membrane potential (TMRE)
and Annexin V positivity in 22Rv1 and PC3 cells treated for the indicated time points with 20mM sorafenib, (means±S.D., nZ3); (c) Immunoﬂourescent staining and
quantiﬁcation of mitochondrial membrane potential (appearing in red, mitotracker) and cytochrome c (appearing in green, FITC) in 22Rv1 and PC3 treated with 20mM
sorafenib for 24h; (d) Immunoblot analysis of the indicated proteins involved in the execution of apoptotic cell death of 22Rv1 and PC3 cells treated with 20mM sorafenib for
48h;(e)QuantitativeanalysisofAnnexinV/PIpositivityin22Rv1andPC3pre-treatedwitheither10mMzVAD.fmkor50mMNecrostatin1followedby20mMsorafenibfor24h
(means±s.d., nZ3)
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Cell Death and Diseasecell death was further examined by transfecting 22Rv1 cells
withaconstitutivelyactiveMEK1construct,MEK1-DD(Figure
2e and f). Notably, MEK1-DD overexpression attenuated the
sorafenib-induced inhibition of ERK1/2 phosphorylation and
the dephosphorylation of the downstream target Bad, yet did
not alter sorafenib-induced Mcl-1 downregulation and clea-
vage (Figure 2e). Importantly, MEK1-DD overexpression
signiﬁcantly inhibited sorafenib-induced cell death in 22Rv1
cells, aneffect thatcouldbe reversedbythe co-administration
of the MEK1 inhibitor U0126 (Figure 2f). The role of Bad in
sorafenib-induced cell death was further substantiated by
depleting 22Rv1 cells from Bad using suitable siRNA. We
found that knocking down of Bad attenuates the cytotoxic
efﬁcacy of sorafenib (Figure 2g and h). Overall these data
suggest that 22Rv1 cells require an active Raf/MEK/ERK
pathway to survive and that interrupting this pathway by
sorafenib leads to the activation of Bad and consequent cell
killing.
Inhibition of the Src–AKT pathway is required for
sorafenib-induced cell death in PC3 cells. Loss of
PTEN expression is frequently observed in prostate cancer.
In PC3 cells, PTEN is not expressed leading to an uninhibited
and constitutively active PI3K/AKT pathway secondary to
upstream tyrosine kinases such as Src.
4 Src and AKT were
constitutively phosphorylated in PC3 cells, and this activation
was largely blocked by sorafenib (Figure 3a). One
downstream target of AKT is the transcription factor FOXO,
which is known to regulate the expression of the BH3-only
protein Bim. Treatment of PC3 cells with sorafenib induced
the expression of the Bim-EL isoform. As expected,
pharmacological inhibition of the PI3K/AKT pathway by
Ly294002 did not induce any signiﬁcant changes in 22Rv1
cells. However, in PC3 cells, Ly294002 had minor cytotoxic
effects, when added alone, and further potentiated sorafenib-
induced cell death (Figure 3b). Transient transfection of PC3
cells with a constitutively active AKT construct led to
protection from sorafenib-induced cell death (Figure 3c and
d). To substantiate the importance of the induction of Bim as
a result of the inhibition of AKT phosphorylation, Bim was
transiently knocked down and the effect of this transfection
on sorafenib-induced cell death was examined by
immunoblotting and ﬂow cytometry (Figure 3e and f).
Knockdown of Bim partially protected PC3 cells from
sorafenib-induced killing, supporting the implication of the
PI3K/AKT/Bim axis in sorafenib-mediated PC3 cell killing.
Furthermore, knocking down of Bak in PC3 cells partially
protects from sorafenib-induced cell death (Supplementary
Figure 2a and b).
Sorafenib induces cytoprotective autophagy in 22Rv1
and PC3 cells. Induction of autophagy in response to TKIs
including sorafenib
14 has been observed by us and others,
and autophagy may contribute or reduce cell death
responses, depending on the metabolic state of the
cells.
20,21 Treatment of 22Rv1 and PC3 with sorafenib-
induced LC3-GFP
þ cytoplasmic foci characteristic of
autophagic vacuoles (Figure 4a and b). Apart from LC3
accumulation in autophagosomes, other hallmarks of
autophagy, such as LC3 lipidation and p62 degradation,
were observed in 22Rv1 and PC3 treated with sorafenib
(Figure 4c). Chemical inhibition of early and late autophagy
with 3-methyladenine or chloroquine did not reduce, but
rather potentiated sorafenib-induced cell death in PC3 cells
to levels similar induced in 22Rv1, suggesting that PC3 cells
activate a cytoprotective autophagic response (Figure 4d).
Transient knockdown of Atg5 in 22Rv1 and PC3 led to
potentiation of sorafenib-induced cell death, further
conﬁrming the cytoprotective role of autophagy in this
context (Figure 4e and f). In summary, these data suggest
that autophagy is induced in response to sorafenib to protect
22Rv1 and PC3 cells and that suppressing autophagy can
improve the efﬁcacy of sorafenib.
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Figure 2 Inhibition of ERK phosphorylation is necessary, but not sufﬁcient for
Sorafenib-induced apoptosis in 22Rv1 cells. (a) Immunoblot analysis of
phosphorylated and total ERK1/2 in 22Rv1 and PC3 cells treated with the
indicated doses of sorafenib for 24h; (b) Immunoblot analysis of phosphorylated
and total ERK1/2 in 22Rv1 and PC3 cells treated with 20mM sorafenib for the
indicated time points; (c) Quantitative analysis of Annexin V/PI positive, 22Rv1 and
PC3 cells pre-treated with U0126 followed by 20mM sorafenib for 24h
(means±S.D., nZ3); (d) Immunoblot analysis of the indicated proteins in
22Rv1andPC3cellstreatedwith 20mMsorafenibfor24h; (e)Immunoblotanalysis
oftheindicatedproteinsin22Rv1transientlytransfectedwitheitheranemptyvector
orconstitutivelyactiveMEK1(MEK1-DD) andtreatedwith 20mM sorafenibfor 24h;
(f)QuantitativeanalysisofAnnexinV/PIpositive,22Rv1cellstransfectedwitheither
an empty vector or with constitutively active MEK1 (MEK1-DD) and treated with
20mM sorafenib for 24h (means±S.D., nZ3, *Po0.05); (g) Immunoblot analysis
of Bad in 22Rv1 cells transiently transfected with either GFP siRNA or with Bad
siRNA and treated with 20mM sorafenib for 24h; (h) Quantitative analysis of
Annexin V/PI positive of 22Rv1 cells transiently transfected with either GFP siRNA
or with Bad siRNA and treated with 20mM sorafenib for 48h (means±S.D., nZ3)
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Cell Death and DiseaseMcl-1 inactivation is required for sorafenib-induced
apoptosis. The dependence of sorafenib-induced cell
death on the downregulation of Mcl-1 protein levels has
been well described for other malignancies.
22 Accordingly,
sorafenib-induced Mcl-1 downregulation in a time and dose-
dependent manner (Figure 5a and b). In 22Rv1, Mcl-1 is
cleaved to the 27kDa fragment, whereas in PC3, Mcl-1 total
protein levels are downregulated. Ectopic overexpression of
wild-type Mcl-1 led to inhibition of sorafenib-induced cell
death in both 22Rv1 and PC3 cells (Figure 5c and d).
As sorafenib targets one of the three main anti-apoptotic
Bcl-2 family members, Mcl-1, we hypothesized that
co-inactivation of Bcl-2 and Bcl-xL by the co-administration
of the Bcl-2/Bcl-xL antagonist, ABT737 should potentiate the
efﬁcacy of sorafenib-induced cell death. Indeed, co-treatment
of 22Rv1 and of PC3 cells with sorafenib and ABT737
signiﬁcantlyimprovedtheefﬁcacyofinvitrochemotherapy,as
compared with treatment with sorafenib alone (Figure 5e and
f). Importantly, such effects were not observed for the
combination of sorafenib with ABT737 in normal prostate
cells (Supplementary Figure 3). Collectively, these data
indicate that the anti-apoptotic Bcl-2 family members Mcl-1,
Bcl-2 and Bcl-xL protect prostate cancer cells from sorafenib-
induced cell death and simultaneous targeting of several anti-
apoptotic proteins can lower the apoptotic threshold of 22Rv1
and PC3 prostate cancer cells.
CAFs protect from sorafenib-induced cell death. It has
recently been suggested that the tumor microenvironment,
apart from promoting tumor growth, might also confer
resistance to therapy.
23 Here, we examined the role of
CAFs in modulating the response of 22Rv1 and PC3 to
sorafenib alone or in combination with ABT737. The
ﬁbroblast nature of the tissue-derived cell cultures was
veriﬁed by their ﬁbroblast-characteristic morphology and the
expression of ﬁbroblast markers such as PDGFR-b, aSMA
but not for example, E-CADHERIN (Figure 6a and b).
Administration of sorafenib for 48h-induced cell death in
22Rv1 and PC3 monocultures, and this cytotoxic effect
abrogated in co-cultures with CAFs (Figure 6c and e).
However, treatment with ABT737 or, more convincingly, with
sorafenib plus ABT737 re-established the sensitivity of
22Rv1 and PC3 cells to cell killing in spite of the presence
of CAFs (Figure 6c and e).
In an attempt to delineate the mechanisms mediating the
cytoprotective effect of CAFs on 22Rv1 and PC3, several key
signaling cascades were examined. The majority of the
signaling cascades examined in this paper were inhibited by
sorafenib eveninthepresenceofCAFs(Figure6d).However,
a major difference was found with respect to ERK phosphor-
ylation, which could not be inhibited any more by sorafenib in
the presence of CAFs. Furthermore, there was an increase in
LC3 lipidation in sorafenib-treated 22Rv1 cells grown in the
presence of CAFs indicative of increased autophagy. In PC3
cells, AKT phosphorylation and Bcl-xL protein levels were
sustained in the presence of CAFs, thus providing survival
signals for PC3 to resist sorafenib-induced cell death
(Figure 6f). Thus, tumor ﬁbroblasts can protect prostate
cancer cells from sorafenib, at last in PC3 by the upregulation
of Bcl- XL and co-administration of ABT737 can revert this
CAF-mediated resistance (Figure 6c and e).
Discussion
In the present study we have delineated the signaling
cascades targeted by sorafenib to induce cell death in two
prostate cancer cells 22Rv1 and PC3. One striking difference
between these two cell lines is that 22Rv1 activate the
apoptotic pathway earlier and to a larger extent than in PC3
cells. In 22Rv1, cytochrome c is released, caspases are
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Figure 3 Inhibition of Src–AKT pathway is required for sorafenib-induced cell
deathinPC3cells.(a)Immunoblotanalysisoftheindicatedproteinsin22Rv1andPC3
cells treated with 20mM sorafenib for 24h; (b) Quantitative analysis of Annexin V/PI
positive,22Rv1andPC3cellspre-treatedwithLY294002followedby20mM sorafenib
for 24h (means±S.D., nZ3); (c) Immunoblot analysis of phosphorylated and total
AKT in PC3 cells transiently transfected with either an empty vector or with
constitutively active AKT and treated with 20mM sorafenib for 24h; (d) Quantitative
analysis of Annexin V/PI positive of PC3 cells transiently transfected with either an
emptyvectororwithconstitutivelyactiveAKTandtreatedwith20mMsorafenibfor24h
(means±S.D., nZ3, *Po0.05); (e) Immunoblot analysis of Bim and cleaved PARP
(cl-PARP)inPC3cellstransientlytransfectedwitheitherGFPsiRNAorwithBimsiRNA
and treated with 20mM sorafenib for 24h; (f) Quantitative analysis of Annexin V/PI
positive of PC3 cells transiently transfected with either GFP siRNA or with Bim siRNA
and treated with 20mM sorafenib for 24h (means±S.D., nZ3, **Po0.01)
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Cell Death and Diseaseactivated and PARP is cleaved, within 24h. In contrast, PC3
cells have to be treated for up to 48h before a substantial
amount of apoptotic cell death can be detected. The kinetic
difference between these two cell lines cannot be explained
by looking into the molecular components of the core
apoptotic signaling cascade. Rather, the signaling cascades
targetedbysorafenibseemtodeﬁnethetimeandtheextentof
the cell death induced.
Oneofthebest-characterizedtargetsofsorafenibistheRaf/
MEK/ERK pathway.
24 This pathway is constitutively active in
22Rv1,butnotinPC3cells.SorafenibpotentlyinhibitstheRaf/
MEK/ERK axis. The importance of the constitutively active
ERK for the survival of 22Rv1 was demonstrated by chemical
inhibitors and molecular activators, indicating that targeting of
this pathway in 22Rv1 cells is critical for their survival. One of
thedownstreamtargets ofERK1/2 isBad,thephosphorylation
of which promotes its interaction with 14-3-3 proteins thereby
preventing it from triggering apoptosis.
25 Sorafenib treatment
led to a decrease in the serine112 phosphorylation of Bad, an
event that was alleviated by the overexpression of the
constitutively active MEK1-DD construct. Nevertheless, as
theprotectionbyMEK1-DDwasnotcomplete,additionallethal
pathwaysmustbeactivatedinaparallelfashionby22Rv1cells
responding to sorafenib.
WithregardtothelackofERKphosphorylationinPC3cells,
it has been previously reported that metastatic cell lines
express low levels of the proteins involved in the Raf/MEK/
ERK axis.
26 However, we did not observe this in PC3 cells as
they expressed high levels of ERK1/2, but there were not
phosphorylated. An alternative possibility that may account
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Figure 4 Sorafenib induces cytoprotective autophagy in 22Rv1 and PC3 cells. (a) Immunoﬂourescent staining of 22Rv1 and PC3 stably transfected with LC3-GFP and
treatedwith20mMsorafenibfor24h;(b)ThepercentageofcellswithLC3-GFPfociwasquantiﬁedbycountingcellsuntreatedortreatedwith20mMsorafenibfortheindicated
time points (means±S.D., n: 3 ﬁelds of 100 cells). (c) Immunoblot analysis of the indicated proteins in 22Rv1 and PC3 cells treated with 20mM sorafenib for 24h.
(d) Quantitative analysis of Annexin V/PI positive, 22Rv1 and PC3 cells pre-treated with either 5mM 3-methyladenine (3-MA) or 10mM chloroquine (CQ) followed by 20mM
sorafenib for 24h (means±SD, nZ3); (e) Immunoblot analysis of the indicated proteins in 22Rv1 and PC3 cells transiently transfected with either GFP siRNA or with atg5
siRNAandtreatedwith 20mM sorafenibfor 24h. (f) Quantitativeanalysisof AnnexinV/PIpositiveof 2Rv1andPC3cellstransientlytransfectedwith eitherGFPsiRNAor with
atg5 siRNA and treated with 20mM sorafenib for 24h (means±S.D., nZ3, *Po0.05)
Pro-apoptotic effects of Sorafenib on prostate cancer cells
P Kharaziha et al
6
Cell Death and Diseasefor the lack of ERK phosphorylation in PC3 cells is the
reported inhibitory phosphorylation of Raf1 by AKT leading to
the inactivation of Raf/MEK/ERK pathway.
27 These two
possibilities may account for the inactive state of ERK1/2 in
PC3 cells and might also explain the attenuated levels of cell
death induced by sorafenib in these cells.
Immunoblot analyses of the kinases activated in PC3 cells
revealed several important observations. Apart from the well-
described loss of PTEN expression and the constitutively
active AKT, PC3 cells exhibited highly activated Src, a NRTK
closely associated with CRPC. Treatment of PC3 cells with
sorafenib-inhibited Src and AKT phosphorylation, correlating
with an increase in Bim expression. The mechanism by which
sorafenibinhibitsSrcandAKTiselusive.Srcactivationcanbe
stimulated by multiple tyrosine kinases such as EGFR,
VEGFR, PDGFR and FGFR.
28 Thus, it is likely that targeted
inhibition VEGFR and PDGFR may be responsible for the
downstream inactivation of Src. The inhibition of AKT
phosphorylation may be wither owing to the inhibition of the
RTK–Src signaling cascades or via the inhibition of the RTK–
PI3K/AKT signaling cascades by sorafenib.
The role of autophagy in modulating the efﬁcacy of cancer
therapy is a conundrum.
20 In some cases, inhibition of
autophagy potentiates the efﬁcacy of cancer therapeutics,
and in other cases induction of autophagy promotes cell
death.
20 In accordance with several reports on autophagy
induction by TKIs we found that sorafenib potently stimulates
autophagy and that autophagy inhibition exacerbated the
apoptotic response of both 22Rv1 and PC3 cells to sorafenib.
One parameter that correlates well with prostate cancer
progression towards CRPC is the expression of the anti-
apoptotic Bcl-2 family members.
29,30 It has been well
documented that one of the mechanisms by which sorafenib
promotes its anti-tumoral effects is via the downregulation of
Mcl-1.
22 Sorafenib-induced Mcl-1 downregulation is mediated
by translational inhibition and this seems to be the case in
PC3,asmRNAlevelsdidnotchangeupontreatment(datanot
shown). In 22Rv1, Mcl-1 is inactivated via a well-described
alternative mechanism, via caspase-dependent cleavage. In
fact, another TKI induces apoptosis in hypereosinophilic cells
via a caspase-3 dependent cleavage of Mcl-1.
31 Our data
conﬁrm the importance of Mcl-1 downregulation in both cell
lines and found that it is pivotal to the execution of cell death
induced by sorafenib. One of the consequences of Mcl-1
inactivation is the ability to sequester and inhibit Bim-induced
cell death.
32 Apparently, in PC3 cells, shifting of the Bcl-2
rheostat towards cell death occurs by inactivating one of the
anti-apoptotic Bcl2 family members, Mcl-1 and by promoting
the expression of the BH3-only protein Bim. In 22Rv1, it is not
Bim, which is even downregulated in response to sorafenib,
but rather it is the dephosphorylation of Bad along with the
inactivation of Mcl-1 that tilts the balance towards cell death.
Despite the profound effects of sorafenib on oncogenic
signaling cascades activated in PC3, cell death did not occur
before 48h and did not affect more than 30–40% of the cells.
The cause of this resistance seems to be the remaining anti-
apoptotic Bcl-2 family members Bcl-2 and Bcl-xL as treatment
with ABT737 alone induces cell death in PC3 cells and the
combination of sorafenib with ABT737 augmented this
cytotoxic effect to levels similar as those detected in 22Rv1.
The tumor stroma and in particular, CAFs can modulate
tumor growth and determine the response to therapy. In
prostate cancer, the tumor stroma activates RTKs in the
prostate cancer cells via the secretion of cytokines (e.g.,
PDGF, VEGF), hence stimulating the oncogenic signaling
cascades Ras/Raf/MEK/ERK and PI3K/AKT.
18 Here, we
found that CAFs protected both 22Rv1 and PC3 cells from
sorafenib-induced cell death. ERK phosphorylation was
inhibited in 22Rv1 cells cultured in the presence of CAFs.
Even though the source of this inhibition is elusive, it is
tempting to speculate that as one of the main targets of
sorafenib in 22Rv1, ERK, is dephosphorylated upon co-
culture with CAFs, 22Rv1 cells become resistant to this TKI.
Furthermore, co-culturing ofthe CAFs with22Rv1leadsto the
downregulation of total Bad protein levels as well as the
induction of Bcl-xL protein, which in turn might render 22Rv1
cells more resistant to sorafenib. Evidence for this possibility
comes from the ABT737-mediated sensitization of 22Rv1
cells to sorafenib. In addition, the observed increase in
autophagy may also protect the 22Rv1 cells from cytotoxic
effects of sorafenib. The highly metastatic PC3 cancer cells
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Figure 5 Mcl-1 downregulation is required for sorafenib-induced apoptosis.
(a) Immunoblot analysis of Mcl-1, Bcl-xL and Bcl-2 in 22Rv1 and PC3 cells treated
with the indicated doses of sorafenib for 24h; (b) Immunoblot analysis of Mcl-1 in
22Rv1 and PC3 cells treated with 20mM sorafenib for the indicated time points;
(c)ImmunoblotanalysisofMcl-1in22Rv1andPC3cellstransientlytransfectedwith
eitheranemptyvectororwild-typeMcl-1followedbytreatmentwith20mMsorafenib
for 48h; (d) Quantitative analysis of Annexin V/PI positive of 22Rv1 and PC3 cells
transiently transfected with either an empty vector or wild-type Mcl-1 followed by
treatment with 20mM sorafenib for 48h (means±S.D., nZ3, *Po0.05);
(e) Immunoblot analysis of the indicated proteins in 22Rv1 cells treated with either
20mMsorafenibalone,with10mMABT737aloneorwithacombinationofsorafenib
and ABT737 for 48h; (f) Quantitative analysis of Annexin V/PI positive, 22Rv1 and
PC3 cells treated with either 20mM sorafenib alone, with 10mM ABT737 alone or
with a combination of sorafenib and ABT737 for 48h (means±S.D., nZ3)
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Cell Death and Diseasewere completely protected from sorafenib-induced cell death
when cultured with CAFs. In this setting, the paracrine
signaling cascades lead to a sustained phosphorylation/
activation of AKT, thereby providing multiple mechanisms of
survival in PC3 cells. Interestingly Bim induction was not
affected by the sustained AKT phosphorylation suggesting
that its expression is regulated by alternative mechanisms.
Importantly, Bcl-xL protein levels were higher in PC3 cells
cultured with CAFs than without CAFs, indicating that this
could be one of the mechanisms by which PC3 cells resist
sorafenib.
Importantly, the observed resistance to sorafenib in 22Rv1
and PC3 cells co-cultured with primary CAFs could be
reverted by the administration of ABT737. This result
indicates that anti-apoptotic Bcl-2 family members are largely
responsible for the lack of efﬁcacy of sorafenib. Addition of
CAFs increased the expression of Bcl-xL in PC3 cells,
indicating that this CAF-induced Bcl-xL must be the target of
ABT737. These data strongly suggest that the combination of
sorafenib with ABT737 or other, more speciﬁc Bcl-xL
inhibitors should be evaluated for the therapy of metastatic
prostate cancer.
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Cell Death and DiseaseMaterials and Methods
Cell lines and culture conditions. 22Rv1 and PC-3 prostate cancer cell
lines were all cultured in RPMI 1640 (Hyclone, Erembodegem, Belgium) enriched
with 10% fetal bovine serum (Hyclone), glutamine (2mM) penicillin and
streptomycin (50mg/ml) (GIBCO, Stockholm, Sweden). CRL-2221, immortalized
normal prostate epithelium, were cultured in Keratinocyte-SFM Medium (GIBCO)
supplemented with L-glutamine, epidermal growth factor and bovine pituitary
extract.All cell lines werekept at 371C ina humidiﬁedair incubatorand5% CO2. All
cell lines were obtained from American Type Culture Collection (Manassas, VA,
USA) and were authenticated by LGC standards cell line authentication service.
PrimaryCAFs. Primary human prostate ﬁbroblast cultures were established as
previously described.
34 In brief, fresh prostate tissue was harvested from cut
surfaces of radical prostatectomy specimens. For morphological control, Giemsa
stained cytological smears were used and parallel histological sections were
reviewed. The tissue samples were diced in about 1mm
3 pieces that were put into
6-well tissue culture plates and ﬁxed in the well under a cover slide. Then 1.5ml Bfs
medium (DMEM (Hyclone) supplemented with 5% FBS (Hyclone), 5% Nu Serum
(BD Biosciences, Stockholm, Sweden), 5mg/ml insulin, 0.5mg/ml testosterone,
4mML-glutamineand1xPenicillin/Streptomycin(Sigma,Stockholm,Sweden))was
added to each well and the tissue pieces were incubated at 371C with 5 % CO2.
Fibroblast-like cells started to migrate out from the tissue between 5 and 15 days
and were passaged when conﬂuent. Cultures at passages 8–11 were used in this
study.
Co-culture experiments. 22Rv1 or PC3 were plated in 12-well plates 2h
before putting cell culture inserts (BD Falcon, Franklin Lakes, NJ, USA), which
contain CAFs. The cells were incubated together overnight in 5% CO2 incubator
before treatment.
Preparation of sorafenib. Sorafenib was provided by Bayer Health-
Care Pharmaceuticals, Inc. (Wayne, NJ, USA). Sorafenib was dissolved in
DMSO and ﬁnal dosing solutions were prepared on the day of use from a
stock solution. In all the experiments, 20mM sorafenib was used unless stated
otherwise.
Antibodies and reagents. The pancaspase inhibitor z-VAD-FMK
(z-Val-Ala-Asp(OMe)-FMK) (MP Biomedicals, Illkirch, France) was used at
10mM, 3-methyladenine (3-MA) (Sigma-Aldrich, Stockholm, Sweden) was
used at 5mM, Necrostatin1 (Sigma-Aldrich) was used at 50mM, Chloroquine
(Sigma-Aldrich Sweden AB, Stockholm, Sweden) at 10mM, ABT737 (active
biochemical Co. Hong Kong, PR China) at 10mM, Rapamycin at 1mM, U0126
(Sigma-Aldrich) at 10mM, LY294002 (Sigma-Aldrich) at10mM.
The primary antibodies used in this study pSrc (Y416), Src, MEK1, phospho-
ERK1/2 (Thr202/Tyr204), ERK1/2 PTEN, cleaved caspase-3, cleaved caspase-7,
cleaved-PARP,phosphor-AKT(Ser473),AKT,pBAD(Ser112),BAD,ATG-5,Mcl-1,
LC3 I/II, Bcl-2, PDGFRb, phosphoY705 STAT3 and STAT3 were obtained from
Cell Signaling Technology (Danvers, MA, USA), p62 from Abnova (Heidelberg,
Germany), Bim from Stressgene (Plymouth Meeting, PA, USA), Bcl-xL from
Transduction Laboratories (Franklin Lakes, NJ, USA), GAPDH and N-cadherin
from Abcam (Cambridge, UK), b-actin from Sigma-Aldrich, Bak, Bax, E-cadherin,
vimentin from BD Biosciences, AIF from Santa Cruz Biotechnology (Heidelberg,
Germany).
siRNA sequences, plasmids and transfections. Transfection with
plasmids and siRNA experiments where performed according to protocols provided
by Invitrogen (Stockholm, Sweden). Lipofectamine 2000 (Invitrogen) was used for
all transfections with Mcl-1, MEK-CA and myrAKT. Oligofectamine (Invitrogen) was
used for transfections of siGFP (Silence, AM4626, Ambion, Stockholm, Sweden),
siATG5 (siATG : 50-GCA GAA CCA UAC UAU UUGGTT-30) and siBim
(SignalSilence Bim siRNA I), siBak (50-GCGAAGUCUUUG CCUUCUC-30), siBad
(50-GAAGGGACUUCCUCGCCCG-30). Mcl-1 wild-type plasmid was produced by
cloning of Mcl-1 segment of Mcl-1PGEX plasmid (kindly provided by Dr Auberger)
into pCDNA3.3, pBabe-Puro-MEK-DD, which expresses activated MEK1-DD
(S218D/S222D) constitutively, and myristoylated AKT plasmids were acquired from
AddGene Inc. (Cambridge, MA, USA).
Assessment of apoptosis and immunostainings for ﬂow
cytometry. Redistribution of plasma membrane phosphatidylserine is a
marker of apoptosis and was assessed by Annexin ﬂuorescein isothiocyanate
(MACS,MiltenyiBiotech,Bergisch Gladbach, Germany).
35 Brieﬂy,2 10
5 cellsper
sample were collected, washed in PBS, pelleted and re-suspended in incubation
buffer (10mM HEPES/NaOH, pH 7.4, 140mM NaCl, 5mM CaCl2) containing
1% Annexin V and PI. Samples were incubated for 10min before analysis on
a ﬂuorescence-activated cell sorter Calibur ﬂow cytometer (Becton Dickinson,
Franklin Lakes, NJ, USA) using Cell Quest software (San Jose, CA, USA).
To detect sorafenib changes in mitochondrial membrane potential, cell were
stained with tetramethylrhodamine ethyl ester perchlorate and measure by ﬂow
cytometry (TMRE; Invitrogen) as previously described.
36 Brieﬂy, 1nM TMRE was
added to 10
6cells and the cells were incubated for 30min. After washing the cells in
PBS and TMRE, they were incubated for 10min in the dark in 100ml of incubation
buffer (10mM HEPES/NaOH, pH 7.4, 140mM NaCl, 5 mMCaC12, 25nM TMRE)
containing 1% Annexin V FLUOS.
Immunocytochemistry. The effect of sorafenib on prostate cancer cell lines
was analysed by staining of mitochondria with MitoTracker and co staining with
cytochrome c antibody as previously described.
37 Brieﬂy, for mitochondrial stainings,
cells were incubated for 30min in normal growth medium containing 5mM
MitoTracker (Mol. Probes, Inc., Stockholm, Sweden). Cells were then cytospun on
glass slides, ﬁxed in 4% PFA for 20min, permeabilized using digitonin diluted in
PBSfor10minandstainedwithanti-cytochromecantibodiesfor1hatRT,followed
by rabbit-anti-mouse FITC-conjugated antibodies (DAKO, Stockholm, Sweden).
For the immunostainings of the primary CAFs, B2500 ﬁbroblasts were seeded on
a gelatin coated, sterile, eight chamber glass slide (Lab-Tek II, Nalge Nunc Int,
Roskilde,Denmark)andallowedtoattachfor24hinincubator.Cellswereﬁxedwith
4% PFA in PBS for 20min at 41C. After incubation with PBS containing 10% goat
serum for 1h at room temperature, the cells were incubated with the indicated
antibodies for 90min at room temperature. Subsequently, the sections were incu-
bated with a texas red - conjugated anti-mouse (Vector Laboratories, Burlingame,
CA, USA) both diluted 1:100 in PBS with 10 % goat serum for 30min at 371C.
The sections were mounted with Vectashield mounting media with DAPI (Vector
Laboratories). The images were recorded on a DAS Leitz DM RB microscope
with a Zeiss Axioplan-2 microscope with a Zeiss dual mode cooled CCD camera
(Zeiss, Stockholm, Sweden) and Axiovision software 4.1 (Stockholm, Sweden).
Cell cycle analysis. We use NucleoCounter NC-3000 from chemometec
(Allerød, Denmark) to analysis cell cycle according to the manufacturer’s
speciﬁcations. One million cells were harvested and washed by PBS then
resuspended in 0.5ml Solution 10 supplemented with 10mg/ml DAPI. Cells were
incubated at 371C for 5min then 0.5ml Solution 11 was added and 30mlo f
suspendedcells wasloaded on two-chamber slide(NC-Slide A2)andcellcyclewas
analyzed by using provided software.
Immunoblot analyses. Cells were harvested and homogenized in RIPA lysis
buffer (10mM Tris, pH 7.2, 150mM NaCl, 1% deoxycholate, 1% Triton, 0.1% SDS,
5mM EDTA) containing complete protease inhibitor cocktail (Roche Diagnostics,
Meylan,France).After1honice,samplesweresonicatedandproteinquantiﬁcation
was carried out using a Bio-Rad protein assay (Bio-Rad, Sundbyberg, Sweden).
Equal amounts of soluble proteins (15–25mg) were denaturated by boiling
and resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to a nitrocellulose membrane. After blocking in
5% non-fat dry milk in PBS for 1h and probing with a speciﬁc primary antibody
and a horseradish peroxidase-conjugated secondary antibody, the protein bands
were detected by chemiluminescence (Supersignal, Pierce, Rockford, IL, USA) and
X-ray ﬁlm exposure (Kodak, Rochester, NY, USA). Protein loading was normalized
by using anti-GAPDH or anti-actin antibodies.
Assessmentofautophagy. FortheLC3-GFPexperiments,22Rv1andPC3
cells were transfected by 4mg of pEGFP-LC3 plasmid (kind gift from Dr Tamotsu
Yoshimori and Dr. Noboru Mizushima from National Institute of Genetics,
Japan) (Kabeya, 2000 no. 4449) using lipofectamine 2000 (Invitrogen) based on
manufacturer’s recommendation. Twenty four hours after transfection the growth
media was replaced by complete RPMI 1640 supplemented with 1mg/ml G418
(Sigma). The cells cultured for 3 weeks under G418 selection pressure, and then
EGFP-LC3-positive cells were selected by MoFlo XDP Cell Sorter (Beckman
Coulter, Bromma, Sweden). Following treatment, the cells were ﬁxed with 4% PFA
and mounted using Vectashield with DAPI. The images were recorded on a Zeiss
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Axiovision software 4.1.
Real-time PCR. Real-time RT PCR was used to measure mRNA expression
(ABI-PRISM7500FastReal-TimePCRsystem,AppliedBiosystemsInc.,FosterCity,
CA, USA). Oligonucleotide primers were designed using Primer Express version 1.0
(Applied Biosystems Inc.). The Real-Time RT-PCR reaction volume was 15ml,
containing 4ng sample, forward primer (ﬁnal concentration 0.4mM), reverse primer
(ﬁnal concentration 0.4mM) and SYBR Green PCR Master Mix- (4309155E, Applied
Biosystems Inc.). The relativedistribution ofthetranscriptsofinterestwas measured;
a CT value was obtained by subtracting the GAPDH CT values from respective target
CT values. The expression of each target was then evaluated by 2
 DCT.
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